<?xml version="1.0" encoding="UTF-8" ?> 
<rss version="2.0"> 
<channel> 
  <title>제약 보도자료 - 뉴스와이어</title>  
  <link>https://www.newswire.co.kr/?md=A01&amp;cat=1000&amp;cat1=1001</link>  
  <description>제약 보도자료 - 뉴스와이어 RSS 서비스</description>  
  <lastBuildDate>Mon, 26 Oct 2026 20:28:06 +0900</lastBuildDate>  
  <copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright>  
  <webMaster>gichan2@newswire.co.kr</webMaster>  
  <language>ko</language>  
 <image> 
  <title>Newswire</title>  
  <url>https://static.newswire.co.kr/images/logo/logo_rss.png</url>  
  <link>https://www.newswire.co.kr</link>  
  <description>Newswire - 보도자료 통신사 뉴스와이어</description>  
 </image> 
  <item> 
  <title><![CDATA[BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045489&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid ...]]></description> 
  <pubDate>Sun, 25 Oct 2026 15:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[비원, ESMO 2026에서 치료가 어려운 간암 및 폐암에 대한 주목할 만한 데이터 발표]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045488&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[산 카를로스, 캘리포니아--(Business Wire/뉴스와이어)--글로벌 종양학 회사인 비원 메디신스 (BeOne Medicines Ltd.)(나스닥: ONC, 홍콩증권거래소: 06160; 상하이증권거래소: 688235)는 유럽 종양학회(European Society for Medical Oncology, ESMO) 2026 학술대회...]]></description> 
  <pubDate>Sun, 25 Oct 2026 15:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045481&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[CAMBRIDGE, England--(Business Wire/Korea Newswire)--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adul...]]></description> 
  <pubDate>Sun, 25 Oct 2026 14:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[문디파마, IDWeek 2026에서 최신 연구 구두 발표 형식으로 ReSPECT 3상 임상시험 추가 결과 발표]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045480&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[캠브리지, 영국--(Business Wire/뉴스와이어)--문디파마(Mundipharma)는 오늘 동종 조혈모세포 이식(allo-HSCT)을 받는 성인 환자의 침습성 진균 질환(IFD) 예방을 위한 레자요(REZZAYO®)(레자펀진 아세테이트)의 글로벌 3상 ReSPECT 임상시험의 추가 결과를 발표했...]]></description> 
  <pubDate>Sun, 25 Oct 2026 14:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045475&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analy...]]></description> 
  <pubDate>Sun, 25 Oct 2026 13:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[비원 메디신스, 1차 치료 HER2+ 위식도암에서 테빔브라-지헤라 병용에서의 지속적인 생존 혜택 보고]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045474&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[산 카를로스, 캘리포니아--(Business Wire/뉴스와이어)--글로벌 종양학 기업인 비원 메디신스(BeOne Medicines Ltd.)(Nasdaq: ONC; HKEX: 06160; SSE: 688235)가 HER2 양성 국소 진행성 또는 전이성 위식도 선암(GEA) 환자의 1차 치료로서 테빔브라(TEVIMBRA®)(티슬...]]></description> 
  <pubDate>Sun, 25 Oct 2026 13:25:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Brenus Pharma’s Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045473&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[MADRID--(Business Wire/Korea Newswire)--Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant...]]></description> 
  <pubDate>Sun, 25 Oct 2026 13:05:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[브레누스 파마의 새로운 체내 면역요법 STC-1010, 1차 치료 MSS 전이성 대장암에서 안전성 입증 및 T세포 활성화, 완전반응 2건 확인]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045472&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[마드리드--(Business Wire/뉴스와이어)--임상 단계 바이오테크 기업 브레누스 파마(Brenus Pharma)는 BreAK CRC-001의 1a상 용량 증량 시험에서 얻은 최초 데이터를 발표했다. 절제 불가능한 환자 9명이 치료를 받았으며, 89%는 간 전이가 있었고 89%는 KRAS 변이 종...]]></description> 
  <pubDate>Sun, 25 Oct 2026 13:05:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045468&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[OSAKA, Japan & CAMBRIDGE, Mass--(Business Wire/Korea Newswire)--Takeda (TSE:4502/NYSE:TAK ) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Cla...]]></description> 
  <pubDate>Sun, 25 Oct 2026 12:40:00 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[포트리아와 오미코, 바이오마커 기반 항암 신약 개발 발전 위한 협력 추진]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045459&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>더럼, 노스캐롤라이나--(뉴스와이어)--글로벌 선도 임상시험수탁기관(CRO)인 포트리아(Fortrea, 나스닥: FTRE, 이하 ‘회사’)와 호주의 대표적인 정밀 종양학 검사 및 임상시험 매칭 기관인 오미코(Omico)는 암 환자들이 바이오마커 특성에 부합하는 임상시험에 참여...]]></description> 
  <pubDate>Sun, 25 Oct 2026 10:34:03 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045428&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[LAUSANNE, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of ...]]></description> 
  <pubDate>Fri, 23 Oct 2026 15:22:39 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045318&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[ZUG, Switzerland--(Business Wire/Korea Newswire)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. · Record net sales of 4.765 billion USD for the fir...]]></description> 
  <pubDate>Thu, 22 Oct 2026 14:48:15 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045210&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[ZUG, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab E...]]></description> 
  <pubDate>Wed, 21 Oct 2026 15:53:51 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[LG화학, AI로 신약 찾고 환자 고른다]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045163&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[<table border=0 align=left cellspacing=0 cellpadding=0 cellpadding=3 style='font-size:100%;font-family:arial,sans-serif'><tr><td width=80 align=center style='padding-left:6px;' valign=top><a href='https://www.newswire.co.kr/newsRead.php?no=&amp;sourceType=rss' target=nw><img src="https://file.newswire.co.kr/data/datafile2/thumb/.jpg" width="80" border="0" /></a></td></tr></table>서울--(뉴스와이어)--LG화학이 AI를 신약개발의 핵심 엔진으로 키운다. 후보물질 발굴부터 임상시험 환자 선별까지 AI 기반 의사결정을 확대해 신약개발 성공 가능성을 높인다는 전략이다. LG화학은 20일 서울 강서구 LG사이언스파크 ISC동에서 LG AI연구원, 미국 바...]]></description> 
  <pubDate>Wed, 21 Oct 2026 10:53:40 +0900</pubDate> 
  </item> 
  <item> 
  <title><![CDATA[BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026]]></title> 
  <link>https://www.newswire.co.kr/newsRead.php?no=1045110&amp;sourceType=rss</link> 
  <category>제약</category> 
  <description><![CDATA[SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at t...]]></description> 
  <pubDate>Tue, 20 Oct 2026 16:40:00 +0900</pubDate> 
  </item> 
</channel> 
</rss> 
